21 May 2026
: Case report
[In Press] Primary Small Cell Neuroendocrine Carcinoma of the Breast in a 75-Year-Old Woman With Aggressive Recurrence Despite Multimodal Therapy: A Case Report and Literature Review
Challenging differential diagnosis, Unusual setting of medical care, Rare coexistence of disease or pathology
Shefa Abdullah AlamoudiDOI: 10.12659/AJCR.952443
Am J Case Rep In Press; DOI: 10.12659/AJCR.952443
Available online: 2026-05-21, In Press, Corrected Proof
Publication in the "In-Press" formula aims at speeding up the public availability of the pending manuscript while waiting for the final publication. The assigned DOI number is active and citable. The availability of the article in the Medline, PubMed and PMC databases as well as Web of Science will be obtained after the final publication according to the journal schedule
Abstract
BACKGROUND
Neuroendocrine breast tumors represent an uncommon subtype of breast cancer, accounting for less than 1% of all breast malignancies and fewer than 0.1% of all neuroendocrine tumors. Their histological and immunophenotypic features closely resemble neuroendocrine neoplasms of other organs, and diagnosis requires careful exclusion of extramammary primaries.
CASE REPORT
We present the case of a 75-year-old woman diagnosed with primary small cell neuroendocrine breast carcinoma following an incidental detection of a right breast mass. She underwent a simple mastectomy with sentinel lymph node biopsy, followed by adjuvant carboplatin-etoposide chemotherapy. One year later, she developed a solitary hepatic metastasis, which was successfully treated with metastasectomy and repeat adjuvant chemotherapy. Despite initial responses, subsequent surveillance imaging demonstrated progressive hepatic metastatic disease. This case underscores the aggressive clinical behavior and diagnostic challenges associated with high-grade neuroendocrine breast tumors. The 2019 WHO classification highlights the importance of distinguishing neuroendocrine carcinoma subtypes due to differing prognostic and therapeutic implications. Although multiple treatment modalities exist, outcomes remain poor in high-grade or advanced disease.
CONCLUSIONS
Neuroendocrine breast tumors remain insufficiently understood because of their rarity. This report highlights the importance of thorough histopathological evaluation, meticulous exclusion of extramammary primaries, and close longitudinal follow-up. Additional research is needed to establish standardized diagnostic and therapeutic guidelines.
Keywords: Breast Diseases; Breast Neoplasms; Case Reports; Literature Review; Neuroendocrine Tumors; Oncology; Rare Diseases
In Press
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.949976
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950290
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950607
Case report
Am J Case Rep In Press; DOI: 10.12659/AJCR.950985
Most Viewed Current Articles
07 Dec 2021 : Case report
17,691,734
DOI :10.12659/AJCR.934347
Am J Case Rep 2021; 22:e934347
06 Dec 2021 : Case report
164,491
DOI :10.12659/AJCR.934406
Am J Case Rep 2021; 22:e934406
21 Jun 2024 : Case report
113,090
DOI :10.12659/AJCR.944371
Am J Case Rep 2024; 25:e944371
07 Mar 2024 : Case report
59,175
DOI :10.12659/AJCR.943133
Am J Case Rep 2024; 25:e943133






